Cancer Immunotherapy with CDK7 Inhibitors
- PMID: 32348731
- DOI: 10.1016/j.trecan.2020.02.005
Cancer Immunotherapy with CDK7 Inhibitors
Abstract
Recent findings demonstrate that pharmacological cyclin-dependent kinase 7 (CDK7) inhibitors can evoke anticancer immunity upon genomic destabilization of neoplastic cells. Besides adding CDK7 to the expanding list of cell cycle proteins that impinge on immune regulation, these results support the value of aggravating genomic instability in cancer cells to enable immunological disease control.
Keywords: PD-1; YKL-5-124; immune checkpoint blockade; micronuclei; small cell lung cancer; type I interferon.
Copyright © 2020 Elsevier Inc. All rights reserved.
Comment on
-
CDK7 Inhibition Potentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung Cancer.Cancer Cell. 2020 Jan 13;37(1):37-54.e9. doi: 10.1016/j.ccell.2019.11.003. Epub 2019 Dec 26. Cancer Cell. 2020. PMID: 31883968 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Medical